Rockefeller Capital Management L.P. Raises Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Rockefeller Capital Management L.P. raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 160,335 shares of the company’s stock after purchasing an additional 2,739 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in AstraZeneca were worth $12,480,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. McClarren Financial Advisors Inc. lifted its position in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new position in shares of AstraZeneca in the 2nd quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca in the 3rd quarter worth approximately $28,000. Hobbs Group Advisors LLC bought a new stake in shares of AstraZeneca in the 2nd quarter valued at approximately $35,000. Finally, Versant Capital Management Inc raised its position in shares of AstraZeneca by 1,614.8% during the 2nd quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock valued at $36,000 after acquiring an additional 436 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

AZN opened at $67.04 on Tuesday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a market capitalization of $207.86 billion, a price-to-earnings ratio of 32.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.45. The business has a 50 day moving average price of $72.27 and a two-hundred day moving average price of $77.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 earnings per share. Research analysts predict that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on AZN. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.